Warshaw Burstein LLP | Warshaw Burstein Advises Nexalin Technology on $5.25 Million Secondary Offering
This links to the home page
News & Publications

Warshaw Burstein Advises Nexalin Technology on $5.25 Million Secondary Offering

07/25/2024
Corporate partners Martin Siegel and Steve Semian, along with tax partner Jason Diener, represented Nexalin Technology, Inc., as securities and general corporate counsel with respect to Nexalin’s public offering of 2,315,000 shares of common stock, which closed on July 1, 2024.

The offering raised gross proceeds of approximately $5.25 million for Nexalin, which trades on the Nasdaq Capital Markets tier of the Nasdaq Stock Market (Nasdaq: NXL; NXLIW).

Read the Nexalin Technology press release here.

About Nexalin Technology, Inc.:
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All Nexalin’s products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: https://nexalin.com/.